Bausch & Lomb Automates Clinical Trial Managementwith Phase Forward InForm

Global Eye Health Company Signs Multi-Year Agreementto Implement Phase Forward`s
EDC Solution
WALTHAM, Mass.--(Business Wire)--
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions
for clinical trials and drug safety, today announced a multi-year contract with
renowned eye health company Bausch & Lomb. The agreement calls for Bausch & Lomb
to implement Phase Forward`s InForm Global Trial Management (GTM) electronic
data capture (EDC) solution, including the Central Coding module, in all of its
trials, including Surgical, Vision Care and Pharmaceuticals products.

Bausch & Lomb will leverage Phase Forward`s InForm GTM to view and act on
clinical trial data earlier in the development cycle, and enhance the efficiency
and effectiveness with which it manages study procedures and expenditures. The
Central Coding module - fully integrated with InForm - will be utilized to
streamline the process of coding medical terms for trials, automating manual
tasks while increasing coding consistency and accuracy.

"Bausch & Lomb is committed to the use of innovative technology to help develop
the highest quality eye health products in the most efficient manner," said John
W. Sheets, Jr., corporate vice president and chief technology officer, Bausch &
Lomb. "Clinical trials are a critical element of our product development engine,
and Phase Forward`s EDC solution brings a proven solution for automating and
optimizing trial management."

"Bausch & Lomb enjoys a worldwide reputation for high quality eye health
products," said Bob Weiler, chairman and CEO, Phase Forward. "We are proud to be
selected by a company of this caliber. Our mission is to become the trusted
partner of all of our customers, and we bring this same commitment to this new
relationship announced today."

About Bausch & Lomb

Bausch & Lomb is dedicated to bringing visionary ideas to eye health. Its core
businesses include contact lenses and lens care products, ophthalmic surgical
devices and instruments, and ophthalmic pharmaceuticals. The Bausch & Lomb name
is one of the best-known and most respected healthcare brands in the world.
Founded in 1853, the company is headquartered in Rochester, N.Y., and employs
more than 10,000 people worldwide. Its products are available in more than 100
countries. More information is available at www.bausch.com.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for
clinical trials and drug safety. Phase Forward`s products and services have been
utilized in over 10,000 clinical trials involving more than 1,000,000 clinical
trial study participants at over 300 organizations and regulatory agencies
worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer
Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline,
Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk,
PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis,
Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines
and Healthcare Products Regulatory Agency. Additional information about Phase
Forward is available at www.phaseforward.com.

Cautionary Statement

Certain statements made in this press release that are not based on historical
information are forward-looking statements which are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. This
press release contains express or implied forward-looking statements relating
to, among other things, the performance and features of Phase Forward`s products
and services, demand for Phase Forward`s products and services, future business
and operations plans of a Phase Forward customer, and the ability of Phase
Forward`s customers to realize benefits from the use of Phase Forward`s products
and services. These statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond Phase
Forward's control, which could cause actual results to differ materially from
those contemplated in these forward-looking statements. In particular, the risks
and uncertainties include, among other things, the ability of Phase Forward`s
customers to realize benefits from the use of its products and services, the
possibility that customers` needs or plans may change over time, the possibility
that the level of demand for Phase Forward`s products and services may vary,
regulatory changes and competition. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. Phase Forward undertakes no obligation to
update or revise the information contained in this press release, whether as a
result of new information, future events or circumstances or otherwise. For
additional disclosure regarding these and other risks faced by Phase Forward,
see the disclosure contained in Phase Forward's public filings with the
Securities and Exchange Commission including, without limitation, its most
recent Annual Report on Form 10-K.

Phase Forward
Elaine Maynard, 781-902-4371
elaine.maynard@phaseforward.com
or
CHEN PR, Inc.
Randy Wambold, 781-672-3119
rwambold@chenpr.com

Copyright Business Wire 2009